Phase 1 Placeholder

This is a placeholder. It's hidden from the grid/chart , but necessary to display the filter option until real projects have this category. Keep the category "Hidden"...

FGFR2/3 / KIN-3248

Our FGFR program, KIN-3248 is a small-molecule kinase inhibitor that target cancer-associated alterations in FGFR2 and FGFR3 genes, which are among the most commonly identified oncogenic drivers detected in solid tumor cancers. KIN-3248 aims to address the primary...

RAF / KIN-2787 Combination

Our lead RAF program, KIN 2787 is a small molecule kinase inhibitor targeting specific classes of BRAF kinase alterations (Class II and Class III) that characterize subsets of melanoma, lung cancer, and other solid tumors. As a pan-RAF kinase inhibitor, KIN-2787...

RAF / KIN-2787 Monotherapy

Our lead RAF program, KIN 2787 is a small molecule kinase inhibitor targeting specific classes of BRAF kinase alterations (Class II and Class III) that characterize subsets of melanoma, lung cancer, and other solid tumors. As a pan-RAF kinase inhibitor, KIN-2787...